Literature DB >> 14628297

Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.

John G Gerber1, Robert J Rhodes, Joseph Gal.   

Abstract

Methadone is a clinically used opioid agonist that is oxidatively metabolized by cytochrome P450 (CYP) isoforms to a stable metabolite, EDDP. Methadone is a chiral drug administered as the racemic mixture of (R)-(-)- and (S)-(+)-methadone, but (R)-methadone is the active isomer. The cytochrome P450 (CYP) isoform involved in methadone's metabolism is thought to be CYP3A4, but human drug-drug interaction studies are not consistent with this. The ability of the common human drug-metabolizing CYPs (obtained from baculovirus-infected insect cell supersomes) to generate 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrilidine (EDDP) from racemic methadone was examined and then determined if the CYP isoforms metabolized methadone stereoselectively. Only CYP2B6, 2C19, and 3A4 generated measurable EDDP from 1 microg/ml of racemic methadone. The hierarchy of EDDP generation was CYP2B6 > CYP2C19 >/= CYP3A4. At 10 microg/ml of methadone, CYP2C9 and CYP2D6 also generated EDDP, but in at least 10-fold lower quantities than CYP2B6. Michaelis-Menten kinetic data demonstrated that CYP2B6 had the highest V(max) (44 ng/min/10pmol) and the lowest K(m) (12.6 microg/ml) for EDDP formation of all the CYP isoforms. In human liver microsomes with high and low CYP2B6 expression but equivalent CYP3A4 expression, high CYP2B6 expression microsomes generated twice the amount of EDDP from 10 microg/ml of methadone than low CYP2B6 expression microsomes. When stereoselective metabolism of racemic methadone by CYP2B6, 2C19, and 3A4 was examined using an enantiospecific methadone assay, CYP2B6 preferentially metabolized (S)-methadone, CYP2C19 preferentially metabolized (R)-methadone, and CYP3A4 showed no preference. These data suggest that multiple CYPs metabolized methadone but CYP2B6 had the highest V(max)/K(m). In addition, only CYP2B6 and 2C19 showed stereoselective metabolism. Our data could explain why the plasma concentration ratio of R/S methadone is variable and why drugs that induce CYP2B6 such as nevirapine and efavirenz also induce methadone metabolism, while the CYP3A4 inducer rifabutin has no effect on methadone pharmacokinetics. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14628297     DOI: 10.1002/chir.10303

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  81 in total

1.  Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene.

Authors:  Hsia-lien Lin; Haoming Zhang; Matthew J Pratt-Hyatt; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2011-09-19       Impact factor: 3.922

2.  Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.

Authors:  Yan Chang; Wenfang B Fang; Shen-Nan Lin; David E Moody
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-09-02       Impact factor: 4.080

3.  Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).

Authors:  Evan D Kharasch; Pamela Sheffels Bedynek; Christine Hoffer; Alysa Walker; Dale Whittington
Journal:  Anesthesiology       Date:  2012-02       Impact factor: 7.892

Review 4.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

Review 5.  Pharmacogenetics of Opioid Use Disorder Treatment.

Authors:  Richard C Crist; Toni-Kim Clarke; Wade H Berrettini
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

6.  Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.

Authors:  Evan D Kharasch; Alysa Walker; Dale Whittington; Christine Hoffer; Pamela Sheffels Bedynek
Journal:  Drug Alcohol Depend       Date:  2009-02-18       Impact factor: 4.492

7.  Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.

Authors:  Evan D Kharasch; Karen J Regina; Jane Blood; Christina Friedel
Journal:  Anesthesiology       Date:  2015-11       Impact factor: 7.892

8.  Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.

Authors:  E D Kharasch; P S Bedynek; S Park; D Whittington; A Walker; C Hoffer
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

9.  Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.

Authors:  Ping Liu; Grover Foster; Robert Labadie; Eugene Somoza; Amarnath Sharma
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

10.  Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.

Authors:  Evan D Kharasch; Darain Mitchell; Rebecka Coles; Roberto Blanco
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.